The Trichoderma citrinoviride VKPM F-1228 strain produces a complex of peptide-based antibiotics with antibacterial and antimycotic action. Synthesis of peptaibols is closely related to the conidiogenesis in the culture. The optimal procedure of the strain cultivation for production of peptaibols is stationary growing for 14 days at a temperature of 28°С and рН 7.5 followed by formation of a dense mycelium film on the modified Saburo medium containing 30 gr/l of glucose and 12.5 gr/l of peptone. Eight individual peptaibols were extracted. The spectrum of their activity was estimated with the use of opportunistic bacteria and micromycetes as well as pathogenic clinical aspergilli. Compounds 9, 13, 14, 15 and 16 were shown active against opportunistic fungi and bacteria including methicilin resistant S.aureus, whereas compounds 9, 13 and 14 in addition showed antimycotic activity against clinical aspergilli.

Oligomycins and their complexes with lithium and zinc were shown to be less active vs. cyclosporin A in inhibition of transport proteins responsible for multiple drug resistance of lymphoid leukosis P388VR cells, while certain oligomycin complexes were tens or hundreds times more active than cyclosporin A by inhibition of transport proteins in another type of tumor cells, i.e. human larynx cancer Hep-2, that makes possible the use of the oligomycins complexes with lithium and zinc for inhibition of multiple drug resistance of certain tumor types.

The effect of two antiseptics, i. e. chlorhexidine bigluconate 0.5% solution and Prontosan® on dual species and monospecies biofilms formed in vitro by the reference strains P.aeruginosa ATCC®27853 and S.aureus ATCC®29213 was examined. It was demonstrated by atomic force microscopy that under the biocide action there occurred phenotype changes of the structural organization of the bacterial biofilms and morphology of the sessile cells: the cocci were lesser in diameter and the rods were reduced. A reliable change of linear cell sizes was accompanied by increase of their roughness (Sq) that was more pronounced for Prontosan®. When assessing the cell viability it was found that Prontosan® inhibited the bacterial viability in mixed and monospecies biofilms formed on both hydrophilic and hydrophobic abiotic surfaces. In the latter case the biofilm biomass (determined by crystal violet assay) lowered in all the variants of the experiment.

The fungal strain INA 01108 producing antibiotic substances with broad spectrum of antibacterial activity was isolated from the natural environment. By the morphological characteristics and DNA analysis it was shown to belong to Ascomycetes of Sordariomycetes. In submerged culture the strain produced at least four antibiotics. The major component of them was identified as eremophilane-type sesquiterpene eremoxylarin A. Eremoxylarin A is effective in vitro against grampositive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin group glycopeptide antibiotics resistant Leuconostoc mesenteroides VKPM B-4177. The efficacy and toxicity of eremoxylarin A was determined on a murine staphylococcal sepsis model. The dose of 6.25 mg/kg provided 100% recovery and survival of the animals, while the dose of 3.12 mg/kg was close to the ED₅₀. The chemical structure of eremoxylarin A allows to modify the antibiotic and such studies may be relevant to design a less toxic derivative without loss of the valuable antimicrobial properties.

Fractions of water soluble and alkali soluble polysaccharides, as well as fucogalactan, a water soluble polysaccharide, and xylomannan, an alkali soluble polysaccharide, were isolated from the Ganoderma lucidum submerged mycelium. When administered orally, the polysaccharides showed antitumor activity in vivo on murine models of solid tumors. Xylomannan and fucogalactan showed the highest antitumor activity. Sensitivity to xylomannan was more pronounced in adenocarcinoma Ca755 as compared to the T-cell lymphocytic leukemia P388. The antitumor activity of the water soluble polysaccharides total fractions from the mycelium and fruiting bodies of the G.lucidum strain was almost identical. The maximum antitumor effect of the mycelium water soluble polysaccharides total fraction was observed with the use of the daily dose of 2 mg/kg.

The frequency of MRSA and MRSE isolates in various units of the Voronezh Regional Hospital was investigated by the results of the local microbiological monitoring for 2014. The maximum position of MRSA was recorded in the ICU (38 to 75% of the strains). The MRSA strains were characterized by higher methicillin resistance, mainly from the cardiosurgical units (60 to 91% of the isolates). The use of the E-test for MRSA susceptibility to vancomycin allowed to estimate the validity of the use of various antibiotics active against MRSA in the treatment of inpatients and to reduce the risk of ineffective therapy.

The aim of the study was to estimate the efficacy of various variants of antibiotic prophylaxis of infectious complications in female patients after histeroscopy. 109 patients were examined. The patients were hospitalized for planned historoscopy. 55 of them were treated prophylactically to prevent infectious complications with a broad spectrum antibiotic administered intravenously 30 min prior to the operation. A course antimicrobial therapy during the postoperative period was applied to 54 females. The results of the trial showed that single administration of an antimicrobial provided high level prevention of infectious complications, whereas the use of course antimicrobial therapy during the postoperative period was of no advantage by the efficacy.

Metaanalysis was applied to the published data on the randomized clinical trials of Remaxol in the treatment of various diseases associated with the liver injury: chronic hepatitis B and C, severe ethanol intoxication, drug-induced pathologies due to tuberculosis chemotherapy, leptospirosis, psoriasis, tumor polychemotherapy. The database included information on 2250 patients. The total number of the patients of the control group (n=1099) were treated according to the routine schemes (active placebo) and that of the main group (n=1151) were additionally treated with Remaxol. Combination of the frequency characteristics of the positive outcomes (% of elimination of the main clinical symptoms and complications) in the patients of the reference groups allowed to estimate the general clinical efficacy of Remaxol, that was equal to 1.75 by the outcome frequency characteristics. The odds ratio of the positive outcomes equaled 5.3 [1.8; 17.0] and the number of the patients needed to treat (NPNT) equaled 8 [6; 14]. Therefore, the infusion Remaxol hepatoprotector based on succinic acid was shown to have statistically and clinally significant therapeutic efficacy in pharmacologic correction of the liver pathologies of diverse genesis.